{"id":"NCT02282813","sponsor":"OPKO Health, Inc.","briefTitle":"Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002","officialTitle":"A Long-term Safety and Efficacy Study of CTAP101 Capsules in Subjects With Stages 3 or 4 Chronic Kidney Disease, Secondary Hyperparathyroidism and Vitamin D Insufficiency (Extension of Study CTAP101-CL-3001 or CTAP101-CL-3002)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04","primaryCompletion":"2015-05","completion":"2015-05","firstPosted":"2014-11-04","resultsPosted":"2016-08-17","lastUpdate":"2016-09-29"},"enrollment":298,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Kidney Disease","Hyperparathyroidism, Secondary","Vitamin D Deficiency"],"interventions":[{"type":"DRUG","name":"CTAP101 Capsules","otherNames":["Calcifediol"]},{"type":"DRUG","name":"Calcitriol","otherNames":["calcifediol"]},{"type":"DRUG","name":"Doxercalciferol","otherNames":["calcifediol"]},{"type":"DRUG","name":"Paricalcitol","otherNames":["calcifediol"]}],"arms":[{"label":"CTAP101 Capsules alone","type":"EXPERIMENTAL"},{"label":"CTAP101 Capsules +calcitriol","type":"EXPERIMENTAL"},{"label":"CTAP101 Capsules +doxercalciferol","type":"EXPERIMENTAL"},{"label":"CTAP101 Capsules +paricalcitol","type":"EXPERIMENTAL"}],"summary":"This extension study of subjects previously enrolled in studies CTAP101-CL-3001 or CTAP101-CL-3002 allows long term evaluation of the safety and efficacy of CTAP101 Capsules in reducing elevated intact parathyroid hormone (iPTH) and correcting vitamin D insufficiency in stage 3 or 4 chronic kidney disease patients.","primaryOutcome":{"measure":"Number of Participants in the Intent to Treat Population With a Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT)","timeFrame":"up to 6 months","effectByArm":[{"arm":"CTAP101 Capsules (Not Randomized; 6 Mos Treatment)","deltaMin":34,"sd":null},{"arm":"CTAP101 Capsules (Not Randomized; 12 Mos Treatment)","deltaMin":66,"sd":null},{"arm":"CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive","deltaMin":30,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1041"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":103},"commonTop":["Anaemia","Nausea","Diarrhoea","Constipation","Urinary tract obstruction"]}}